Compare ARK Genomic Revolution ETF (ARKG) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs UiPath Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while UiPath Inc trades at $11.79 (market cap $6.05B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | PATH | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $19.29 |
52-Week Low | $23.09 | $9.38 |
Market Cap | — | $6.05B |
Enterprise Value | — | $4.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
UiPath (PATH) trades at $11.68, down 1.02% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while narrowing losses from -$74M to projected $327M profit. Recent product launches like Maestro Case expand enterprise automation capabilities. Analyst consensus price target sits at $13.33, representing 14% upside potential from current levels.
PATH presents a compelling growth story with strong revenue expansion and path to profitability, though elevated valuation multiples and competitive pressures warrant caution. The stock's current pullback offers entry opportunity for investors bullish on enterprise automation adoption, with key risks including execution on AI strategy and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
